Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
|Videos|September 1, 2022
Background of UReTER Mentorship Program for underrepresented populations in urology
Author(s)Urology Times staff
Advertisement
In this video Micha Yin-Zheng Cheng, MD, MPH, MS, a resident in the University of California San Francisco (UCSF) Department of Urology discusses the background of the
The 2021 AUA Census found that 2.4% of Urologists identify as Black & 4.4% as Hispanic. The UReTER Mentorship Program was created by residents in the UCSF Department of Urology as a resource for BIPOC (Black, Indigenous, People of Color) and Latinx Urology applicants. According to the program mission, its goal is to “create an annual opportunity for Urology to improve its diversity through resident-led mentorship of applicants who are underrepresented in our field.
Advertisement
Related to this article
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
Engy Habashy, MD, on the role of androgens in GSM management
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5